Enovis vs Insulet
Insulet reported revenue of $2.7 billion in fiscal 2025, 1.2 times Enovis' $2.2 billion in fiscal 2025. Enovis' revenue grew 6.7% in its latest year, and Insulet's grew 30.7%. Enovis had an operating margin of -50.0%, against 17.5% at Insulet. Free cash flow was $20 million at Enovis and $378 million at Insulet.
Side by side
| Enovis | Insulet | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2.2B | $2.7B |
| Revenue growth | 6.7% | 30.7% |
| Revenue growth a year, last 5 years | 14.9% | 24.5% |
| Gross margin | 59.8% | 71.6% |
| Operating margin | −50.0% | 17.5% |
| Net margin | −52.7% | 9.1% |
| Free cash flow | $20M | $378M |
| Free cash flow margin | 0.9% | 13.9% |
| Return on capital | −26.9% | 20.4% |
| Net debt to EBITDA | 5.7x | 0.4x |
| Dividends and buybacks | $4M | $60M |
| Change in diluted share count | 3.2% | −2.7% |
| Last close | $21.16 | $149.26 |
| P/E at the last close | — | 28.0× |
| Insider trades, last 12 months | bought $762,432, sold $45,298 | bought $2.9 million, sold $602,397 |
| Piotroski F-score | 4 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
EnovisInsulet
Operating margin
Percent of revenue
EnovisInsulet
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EnovisInsulet